Sapecmeran autogene
Highest phase reached
Phase 2
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Oligonucleotide
- Drug name
- Sapecmeran autogene
- grt r902
- Grt-r902
- GRT-R902
- RNA (venezuelan equine encephalitis virus-derived construct GRT-R902 structural polyprotein gene deletion-containing plus tumor-specific neoantigen prototype cassette-expressing)
- rna venezuelan equine encephalitis virus derived construct grt r902 structural polyprotein gene deletion containing plus tumor specific neoantigen prototype cassette expressing
- sapecmeran autogen
- Sapecmeran autogen
- sapecmeran autogene
- Sapecmeran autogene
- sapecmeran autogene [INN]
- SAPECMERAN AUTOGENE [USAN]
- Sapecmeran autogene [WHO-DD]
- sapecmeran autogene inn
- sapecmeran autogene usan
- sapecmeran autogene who dd
- self amplifying mrna samrna vector based on venezuelan equine encephalitis virus veev sequences encoding the structural proteins of veev are deleted and replaced by a patient specific cassette expressing 20 tumor specific neoantigens tsnas the vector encodes the veev proteins as well as the 5ʹ and 3ʹ rna sequences required for rna replication but encodes no structural proteins so no infectious viral particle is formed the veev subgenomic 26s promoter located 5ʹ of the inserted tsna cassette drives expression of the tsnas the patient specific tsna cassette is inserted into the grt r902 puc02 atg vee egfp backbone vector this plasmid is used as a template to synthesize the drug substance by in vitro transcription which is then formulated using lipid nanoparticles to make the patient specific vaccine the sequence of the tsna cassette is different for each patient and is designed by the proprietary algorithm edge based on the tumor specific information derived from each patient
- Self-amplifying mRNA (samRNA) vector based on Venezuelan equine encephalitis virus (VEEV). Sequences encoding the structural proteins of VEEV are deleted and replaced by a patient-specific cassette expressing 20 tumor-specific neoantigens (TSNAs). The vector encodes the VEEV proteins as well as the 5ʹ and 3ʹ RNA sequences required for RNA replication but encodes no structural proteins, so no infectious viral particle is formed. The VEEV subgenomic 26S promoter located 5ʹ of the inserted TSNA cassette drives expression of the TSNAs. The patient-specific TSNA cassette is inserted into the GRT-R902 (pUC02-ATG-VEE-eGFP) backbone vector. This plasmid is used as a template to synthesize the drug substance by in vitro transcription, which is then formulated using lipid nanoparticles to make the patient-specific vaccine. The sequence of the TSNA cassette is different for each patient and is designed by the proprietary algorithm EDGE based on the tumor-specific information derived from each patient.
- CAS registry numbers
- 2805319-17-7
- ChEMBL ID
- CHEMBL6068291
- FDA ingredient codes (UNII)
- 2E99S2VU5M
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -meran
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004142
- Subject identifier
- D015179
- Condition
- Colonic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004288
- Subject identifier
- D003110
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021063
- Highest recorded phase
- 2
- NCT05141721
- NCT05456165
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (4)
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
- A Study of a Personalized Neoantigen Cancer Vaccine
- Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
- Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)
In development for (3)
- Colonic neoplasm Phase 2
- Colorectal neoplasm Phase 2
- Neoplasm Phase 2